bioAffinity Technologies Announces Hong Kong Patent for Lung Cancer Test

What Happened

• On September 17, 2026, bioAffinity Technologies, Inc. (a Delaware corporation) announced via press release and Form 8-K (Item 8.01) that the Hong Kong Intellectual Property Department granted a patent for the company’s proprietary technology. The patented method predicts the likelihood of lung cancer by using flow cytometry and fluorescent markers to characterize cell populations in sputum.

Key Details

• Patent granted by the Hong Kong Intellectual Property Department (announcement and Form 8-K filed Sept 17, 2026).
• Technology covers predicting lung cancer using flow cytometry and fluorescent markers to analyze sputum cell populations.
• Company attached the press release as Exhibit 99.1 to the Form 8-K.

Why It Matters

• A granted patent strengthens bioAffinity’s intellectual property protection for its lung cancer prediction technology, which can help guard against competitors and support future commercialization or licensing efforts.
• For investors, the patent is a concrete milestone in the company’s technology development and IP portfolio; it may affect strategic value though the filing does not disclose financial impacts or timelines for commercialization.